Replies to post #66987 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

And, of course, NWBO issued a firm rebuttal of AF's 'article' a day later:-

Company Refutes Latest Feuerstein False Headline and Attacks

BETHESDA, Md., June 20, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein’s latest false headline and attack on the Company, and reaffirmed the Company’s recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors.

The Company’s DCVax-Direct trial is ongoing. Contrary to Feuerstein’s sensationalized false headline, the Company has not received a “rebuke” from any clinical trial site, nor does the Company believe there is any basis for any such “rebuke.”

The Company has consistently said that it would release interim data on an ongoing basis during the course of its DCVax-Direct Phase I/II trial. This trial is a single-arm, unblinded, “open label” trial, meaning that all of the patients in the trial are receiving the DCVax-Direct treatment, and the clinical results in patients are visible to the Company as the trial goes along.

There has been significant interest in this trial, and the Company has been receiving many requests for data updates, as this trial is testing a novel treatment for patients with late stage, inoperable tumors – patients for whom there are virtually no treatment options today. The data released by the Company came from the medical files at the clinical trial sites and reviews of imaging and biopsies, and was provided by the sites and pathology labs, as well as a respected and independent clinical research organization (CRO) managing the trial.

Contrary to Feuerstein’s assertions of promotional claims by the Company, in fact the Company has taken extra care to emphasize in its announcements that the data being reported are only early, initial and partial results. The Company has expressly explained in each announcement that the patients are only part way through the treatment regimen, and the Company specifically cautioned that the data could get either better or worse as more data are collected.

Also contrary to Feuerstein’s attack, it is neither unusual nor inappropriate for interim results from unblinded, open label trials to be reported, particularly in the case of a novel technology in a particularly difficult disease setting that is the subject of significant scientific, clinical and public interest. In such cases, both companies and researchers frequently provide interim data and/or case studies.

Linda Powers, CEO of NW Bio, commented: “As NW Bio continues to make strong progress in multiple programs with two product lines, for both operable and inoperable tumors, and as NW Bio’s clinical programs show encouraging early effects, Feuerstein seeks ever more sensationalized ways to try to smear the Company. This is not even the semblance of professional analysis. We condemn this attack campaign and appreciate the strong support we are receiving from shareholders, patients and other commentators. We intend to continue our progress undeterred.”

There never was a 'firm rebuke' issued by MD Anderson. That phrase was purely an invention by AF based on an apparent phone conversation with Buzdar the day before.

And the HKH lawfirm are repeating the falsehood to this day.

Appalling.